Skip to content
The Policy VaultThe Policy Vault

Ogsiveo (nirogacestat)United Healthcare

Desmoid tumors

Initial criteria

  • Diagnosis of desmoid tumor
  • Disease is progressive
  • Patient requires systemic treatment

Reauthorization criteria

  • Patient does not show evidence of progressive disease while on Ogsiveo therapy

Approval duration

12 months